Document is current
Any future updates will be listed below
-
Authors
Hannemann, Wiebke https://orcid.org/0000-0002-7786-8831
Stahuber, Lukas https://orcid.org/0009-0009-8964-0955
Kouba, Tomas https://orcid.org/0000-0002-1765-9886
Lindenberg, Katrin S. https://orcid.org/0000-0002-8516-0577
Rapp, Daniel https://orcid.org/0000-0003-0453-7318
Lewerenz, Jan https://orcid.org/0000-0002-9272-529X
Huppertz, Hans-Jürgen https://orcid.org/0000-0003-3856-9094
Tykalova, Tereza https://orcid.org/0000-0003-1156-3709
Rusz, Jan https://orcid.org/0000-0002-1036-3054
Landwehrmeyer, G. Bernhard https://orcid.org/0000-0003-3375-790X
Mühlbäck, Alzbeta https://orcid.org/0000-0002-0385-3071
-
Funding
Funding for this research was provided by:
Department of Neurology, Ulm University (Project Voice-HD)
European Union – Next Generation EU: National institute for Neurological Research (ID Project No. LX22NPO5107)
Czech Ministry of Health (grants nr. MH CZ- DRO-VFN64165, NW25-04-00052)
Czech Technical University in Prague (grant SGS “Biological Signal Analysis, Modelling, Interpretation”)
Czech Ministry of Education (Project Cooperation LF1, research area Neuroscience)
Universität Ulm
- License Information
-
More Information
Article History
Received: 7 June 2025
Revised: 11 July 2025
Accepted: 31 July 2025
First Online: 15 October 2025
Declarations
:
: The authors have no competing interests to declare that are relevant to the content of this article. A.M., K.S.L., G.B.L: Their institutions have received compensation for clinical trial services from the following companies: Hoffmann-La Roche, Novartis, Prilenia, Wave, SOM Biotech and from the CHDI Foundation as well as non-financial support (travel and accommodation reimbursement) from European Huntington´s Disease Network. W.H., L.S.: The authors received travel and accommodation reimbursement from European Huntington´s Disease Network. T.K., T.T., J. R., H.J.H, D.R.: The authors have no relevant financial or non-financial interests to disclose. J.L.: reports travel honoraria and speaker’s fees from the CHDI Foundation, the Movement Disorders Society as the German Society for Cerebrospinal Fluid Diagnostic and Clinical Neurochemistry (DGLN), Alexion, Biogen, Sanofi, Teva, Merck, Novartis, Janssen, Fujirebio, Roche, and Neuraxpharm. His institution received financial compensation for clinical trials with JL as principal investigator from CHDI and SOM Biotech. He is member of the executive board of the DGLN. He received research funding from the German Federal Ministry of Education and Research (BMBF, CONNECT-GENERATE, 01GM1908B und 01GM2208B) and the Boehringer Ingelheim University Biocenter.
: The study was approved by the Ethics Committee of the Ulm University, Germany (approval number: 381/18) and was conducted in accordance with the ethical standards laid down in the Declaration of Helsinki of 1964 and its later amendments.
: All individual participants included in the study provided written informed consent for their participation.
